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Tacrolimus,animmunosuppressantwithnarrowtherapeuticwindow,hasbeenusedwidelyintransplantpatients.Grapefruitjuice
and pomelo have been reported to increase the blood levels of tacrolimus. Zhi Ke and Zhi Shi, the ripe peels and unripe fruits of
Citrus aurantium which is chemotaxonomically related to grapefruit and pomelo, are in wide use in clinical Chinese medicine.
To investigate the possible interaction of these two Citrus herbs with tacrolimus, male Sprague-Dawley rats were orally given
tacrolimus (1.5mg/kg) with and without Zhi Ke and Zhi Shi decoctions in a cross-over design. Blood samples were withdrawn via
cardiopuncture at speciﬁc time and quantitated by a microparticle enzyme immunoassay. In addition, to explore the mechanism
of interaction, LS 180 cell line was used for the transport study of rhodamine 123, a typical substrate of P-glycoprotein (P-gp). The
results showed that Zhi Shi signiﬁcantly decreased the Cmax and AUC0−t of tacrolimus by 72.4% and 72.0%, respectively, whereas
Zhi Ke did not aﬀect tacrolimus pharmacokinetics. LS 180 cell line study indicated that Zhi Shi increased the eﬄux activity of
P-gp, enabling us to explain the decreased oral bioavailability of tacrolimus caused by Zhi Shi. Hence, we suggest that Zhi Shi be
contraindicated for transplant patients treated with tacrolimus to reduce the risk of allograft rejection.
1.Introduction
Zhi Ke and Zhi Shi, the dried ripe peels and unripe fruits
of Citrus aurantium, respectively, are widely used in clinical
Chinese medicine. The ripe fruits were harvested in July and
the unripe ones were harvested earlier in May-June. Zhi Ke
was clinically used in easing pain of epigastrium or abdomen
and poor appetite due to stagnation of spleen and stomach
[1]. The constituents in Zhi Ke include naringin, naringenin,
hesperidin, neohesperidin, β-carotene, l-carotene, citraurin,
synephrine, N-methyltyramine, auraptenol, aurantiamaric
acid, aurantiamarin, and so forth [2, 3]. In contrast, Zhi Shi
wasoftenprescribedforgastrointestinaldiseasessuchasfood
retention, constipation, distention of chest, and epigastrium
[1].TheconstituentsinZhiShiincludenaringin,naringenin,
hesperidin, neohesperidin, β-carotene, l-carotene, citrau-
rin, synephrine, N-methyltyramine, auraptenol, rhoifolin,
lonicerin, poncirin, limonin, 5-O-desmethylnobiletin, and
so forth [2, 3].
Tacrolimus, a lipophilic macrolide isolated from Strep-
tomyces tsukubaensis, is an important immunosuppressant
widely used in transplant patients, but with narrow thera-
peutic window. The half-life of tacrolimus in human is 8.7–
11.3h [4]. The adverse eﬀects of tacrolimus included neu-
rotoxicity, nephrotoxicity, gastrointestinal toxicity, hyper-
kalaemia, hypertension, and myocardial hypertrophy [5–8].
On the contrary, subtherapeutic level of tacrolimus may
result in acute rejection of xenografts [9, 10]. Therefore,
whatever signiﬁcantly aﬀecting the absorption or disposition
of tacrolimus is of clinical importance. Tacrolimus is known
as a substrate of P-glycoprotein (P-gp), a multidrug eﬄux
transporter, and cytochrome P450 3A4 (CYP3A4) [11–13].
Consequently, any modulator of P-gp or CYP3A4 may alter
the pharmacokinetics of tacrolimus.
In recent decades, several clinical studies have found
that grapefruit juice and pomelo signiﬁcantly increased the
blood levels of tacrolimus [14–18] .T h ef r u i t so fCitrus
aurantium share many common constituents with grapefruit
and pomelo, such as naringin, naringenin, hesperidin, and
so forth [3]. Therefore, we suspect that Zhi Ke and Zhi
Shi may be subject to relevant interaction with tacrolimus
as grapefruit juice and pomelo did [15–18]. Our previous2 Evidence-Based Complementary and Alternative Medicine
study has reported that Zhi Ke signiﬁcantly increased the
oral bioavailability and toxicity of cyclosporine in pigs [19].
Another study found that Zhi Shi signiﬁcantly decreased the
oral bioavailability of cyclosporine in rats [20]. This study
in turn investigated the eﬀects of Zhi Ke and Zhi Shi on
the pharmacokinetics of tacrolimus in rats. Furthermore,
possible mechanism of interaction was explored by using cell
line model.
2. Methods
2.1. Chemicals. Tacrolimus (Prograf, 5mg/mL) was pur-
chased from Fujisawa Pharmaceutical Company (Osaka,
Japan). The crude drugs of Zhi Ke and Zhi Shi were
purchased from a Chinese drugstore in Taichung and
identiﬁed by microscopic examination. The specimens were
deposited at the Institute of Chinese Pharmaceutical Sci-
ences. Dimethyl sulfoxide (DMSO), 3-(4 ,5  -dimethylthi-
azol-2 -yl)-2,5-diphenyltetrazolium bromide (MTT), rho-
damine 123, sodium dodecyl sulfate (SDS), Triton X-100,
and verapamil were obtained from Sigma (St. Louis, MO,
USA). 6,7-Dimethoxycoumarin was purchased from Aldrich
(Milwaukee, WI, USA). Dulbecco’s Modiﬁed Eagle Medium
(DMEM), trypsin/EDTA, nonessential amino acid, Hank’s
Buﬀered Salt Solution (HBSS), and 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES) were purchased
from Invitrogen (Grand Island, NY, USA). IMx kit was
supplied by Abbott Laboratories (Abbott Park, IL, USA).
Milli-Q plus water (Millipore, Bedford, MA, USA) was used
for all preparations.
2.2. Instrumentation. The HPLC apparatus included a pump
(LC-10AS, Shimadzu, Japan) and an UV/VIS detector (SPD-
10A, Shimadzu, Japan). The RP-18e column (Apollo, 5μm,
250 × 4.6mm) was equipped with a guard column (LiChro-
spher 100, 5μm). The mobile phase consisted of acetonitrile
and water at a ratio of 22:78 (v/v). The UV detector was set
at 280nm, and the ﬂow rate was 1.0mL/min.
2.3. Preparation and Characterization of Zhi Ke and Zhi Shi
Decoctions. To prepare decoctions, 25g of Zhi Ke or Zhi
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a gas stove. After boiling, the mixture was heated gently
until the volume of decoction was reduced to less than
100mL. The mixture was ﬁltered while hot, and suﬃcient
hotwaterwasaddedtomake100mL.Characterizationofthe
decoctions was carried out through quantitation of naringin
and naringenin by HPLC following a previous method
with little modiﬁcation [19]. Brieﬂy, 3.0mL of decoction
was mixed with 7.0mL of methanol, and centrifuged at
10,000g for 15min. A portion of the supernatant was mixed
with equal volume of methanol containing 40.0μg/mL of
6,7-dimethoxycoumarin as internal standard. After ﬁltered
through 0.45μm ﬁlter, the sample was subject to HPLC
analysis. The remaining decoction was frozen at −30
◦Cf o r
later use.
2.4. Animals and Drug Administration. Male Sprague-
Dawley rats were supplied by National Laboratory Animal
Center (Taipei, Taiwan) and kept at least 1 week under
environmentally controlled conditions with free access to
food and water before experiment. After overnight fast, six
rats aged 8–12 weaks and weighing 300–400g were given
1.5mg/kg of tacrolimus orally with and without decoction
of Zhi Ke or Zhi Shi (2g/kg) in a cross-over design.
Drug administration was carried out via gastric gavage, and
the decoctions were given 10min before tacrolimus. Equal
volumeofwaterasthedecoctionwasadministeredascontrol
vehicle. Food was withheld for another 3h after dosing.
One-week was allowed for washout between two treatments.
All animal experiments adhered to “The Guidebook for the
Care and Use of Laboratory Animals (2002)” (Published by
the Chinese Society of Animal Science, Taiwan), and the
experimental protocol had been reviewed and approved by
the Institutional Animal Care and Use Committee of China
Medical University, Taiwan.
2.5. Blood Collection and Determination of Tacrolimus Blood
Concentration. Blood samples (0.3mL) were withdrawn via
cardiopuncture at 0, 5, 15, 30, 60, 120, 240, and 480min after
oral dosing of tacrolimus. Blood samples were collected in
vacutainer tubes containing EDTA and analyzed within 24h.
Blood tacrolimus concentration was assayed by a
microparticle enzyme immunoassay (MEIA) using IMx kit.
Alltheprocedures,calibrationcurve,andvalidationfollowed
the working protocols provided by the supplier. The assay
was calibrated from 3.0 to 30.0ng/mL, and the lower limit
of detection was 1.5ng/mL.
2.6. Cell Line. LS 180, the human colon adenocarcinoma
cell line, was obtained from the Food Industry Research
and Development Institute (Hsinchu, Taiwan). Cells were
cultured in DMEM medium supplemented with 10%
fetal bovine serum (Biological Industries Ltd., Kibbutz
Beit Haemek, Israel), 0.1mM nonessential amino acid,
100units/mL of penicillin, 100μg/mL of streptomycin, and
292μg/mL of glutamine. Cells were grown at 37◦Ci na
humidiﬁed incubator containing 5% CO2. The medium was
changed every other day, and cells were subcultured when
80% to 90% conﬂuency was reached.
2.7. Cell Viability Assay. The eﬀects of Zhi Shi decoction,
verapamil, and DMSO on the viability of LS 180 cells was
evaluated by MTT assay [21]. Cells were seeded into a 96-
well plate. After overnight incubation, the tested agents were
added into the wells and incubated for 72h, then 10μLo f
MTT (5mg/mL) was added into each well and incubated
for additional 4h. During this period, MTT was reduced
to formazan crystal by live cells. Acid-SDS (10%) solution
was added to dissolve the purple crystal at the end of
incubation, and the optical density was detected at 570nm
by a microplate reader (BioTex, Highland Park, Winooski,
VT, USA).
2.8. Transport Assay. The transport assay of rhodamine 123
was modiﬁed from a previous method [22]. Brieﬂy, LS 180
cells (1 × 105)w e r ec u l t u r e di ne a c hw e l li na9 6 - w e l lp l a t e .Evidence-Based Complementary and Alternative Medicine 3
Table 1:Pharmacokineticparametersoftacrolimusinsixratsgiven
tacrolimus (1.5mg/kg) alone and coadministered with 2g/kg of Zhi
Ke and Zhi Shi decoctions.
Parameter Treatment
Tacrolimus
alone
Tacrolimus +
Zhi Ke
Tacrolimus +
Zhi Shi
Tmax (min) 22.5 ±8.22 7 .5 ±6.12 5 .0 ±7.7
Cmax (ng·mL−1)1 9 .2 ±4.2a 17.7 ±4.8 5.3 ±0.8b
(−72.4%)
AUC0−480
(ng·min·mL−1) 2485.4±964.2a 2330.5±268.8a 696.2 ±182.5b
(−72.0%)
MRT (min) 144.3 ±15.2 147.6 ±9.1 127.0 ±29.9
Tmax:t i m et or e a c hCmax.
Cmax: the peak blood concentration.
AUC0−480: area under the blood concentration-time curve to 480 min.
MRT: mean residence time.
Data expressed as mean ± S.D. Means in a row without a common
superscript diﬀer, P<. 05.
After overnight incubation, the medium was removed and
washed three times with ice-cold PBS buﬀer. Rhodamine
123 in HBSS (10μM, 100μL) was added into each well and
incubated at 37◦C. After 1-h incubation, the supernatants
were removed and washed for three times with ice-cold PBS.
Then, Zhi Shi decoction, verapamil (as positive control) and
DMSO were added to correspondent wells and incubated
at 37
◦C. After 4-h incubation, the medium was removed
and the cells were washed three times with ice-cold PBS.
Subsequently, 100μL of 0.1% Triton X-100 was added to lyse
the cells and the ﬂuorescence was measured with excitation
at 485nm and emission at 528nm. To quantitate the content
o fp r o t e i ni ne a c hw e l l ,1 0 μL of cell lysate was added to
200μL of diluted protein assay reagent (Bio-Rad, Hercules,
CA, USA) and the optical density was measured at 570nm.
The relative intracellular accumulation of rhodamine 123
was calculated by comparing with that of control.
2.9. Data Analysis. Noncompartment model of WinNonlin
(version 1.1, SCI software, Statistical Consulting Inc., Apex,
NC, USA) was used for the computation of pharma-
cokinetic parameters of tacrolimus. The area under the
blood concentration-time curve (AUC0−t) was calculated
by the trapezoidal rule to the last point. Pharmacokinetic
parameters among various treatment groups were compared
using one-way ANOVA with Scheﬀe’s test, taking P<. 05 as
signiﬁcant.
3. Results
Figure 1 is the pictures of crude drugs of Zhi Ke and
Zhi Shi. Quantitation results showed that the contents of
naringin and naringenin in Zhi Ke decoction were 280. 5 and
5.0μg/mL, respectively, and in Zhi Shi decoction were 164.3
and 5.2μg/mL, respectively.
Figure 2 depicts the mean blood concentration—time
proﬁles of tacrolimus after treatments with tacrolimus alone
and coadministered with Zhi Ke and Zhi Shi decoctions in
(a)
(b)
Figure 1: Crude drugs of Zhi Ke (a) and Zhi Shi (b).
rats. The pharmacokinetic parameters of tacrolimus after
various treatments are listed in Table 1. Following coadmin-
istration with Zhi Ke, the blood proﬁle of tacrolimus was
essentially superposable with that of control. Nonetheless,
the blood levels of tacrolimus were markedly decreased
since the very early absorption phase upon coadministration
with Zhi Shi, which signiﬁcantly decreased the peak blood
concentration(Cmax)andareaundertheconcentrationcurve
(AUC0−t) of tacrolimus by 72.4% and 72.0%, respectively.
The time to peak concentration (Tmax) and mean residence
time (MRT) of tacrolimus were not aﬀected.
To explore the mechanism of Zhi Shi-tacrolimus inter-
action, LS 180 cell model was used for the transport assay
of rhodamine 123. Through MTT assay, Zhi Shi decoction
showed no signiﬁcant inﬂuence on cell viability at the tested
concentrations. In transport study, the intracellular accu-
mulation of rhodamine 123 measured after 4-h incubation
with tested agents is shown in Figure 3. The positive control
verapamil (200μM) signiﬁcantly increased the intracellular
accumulation of rhodamine 123 by 46.5%. On the contrary,
Zhi Shi signiﬁcantly reduced the intracellular accumulation4 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Eﬀects of Zhi Shi (mg/mL) and verapamil (V, 200μM) on
the accumulation of rhodamine 123 in LS 180 cells. Data expressed
as mean ± S.D. ∗P<. 05, ∗∗P<. 01, ∗∗∗P<. 001.
of rhodamine 123 by 39.0–13.9% at the concentration range
of 0.8–12.5mg/mL.
4. Discussions
In this study, a rat model was employed to evaluate the
eﬀects of two Citrus herbs on tacrolimus pharmacokinetics.
The markedly decreased Cmax and AUC0−t of tacrolimus
caused by coadministration of Zhi Shi indicated that the
oral bioavailability of tacrolimus was signiﬁcantly reduced,
whereas Zhi Ke did not alter tacrolimus bioavailability.
These results are similar to our previous work reporting
the eﬀects of Zhi Ke and Zhi Shi on the pharmacokinetics
TAC
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Blood
TAC-M
Enterocyte
ADP ADP ATP ATP ADP ATP
CYP3A CYP3A
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Figure 4: Illustration of the inhibition of Zhi Shi on tacrolimus
(TAC) absorption through activating the eﬄux function of P-gp on
the cell membrane of enterocytes. TAC-M: TAC metabolites.
of cyclosporine, also a substrate of P-gp and CYP 3A4, in
rats [20]. For clinical implication, we strongly suggest that
concurrent use of Zhi Shi with cyclosporine or tacrolimus
should be avoided to reduce the risk of allograft rejection.
Grapefruit juice and pomelo have been well known in
that they could elevate the blood levels of cyclosporine
and tacrolimus [14, 15, 17, 18, 23, 24]. So far, many
constituents have been identiﬁed to be the possible causative
agents for the interactions between grapefruit juice and
western medicines, which were substrates of P-gp or/and
CYP3A4 [25]. Among the putative causative constituents,
6 ,7  -dihydroxybergamottin and bergamottin, two minor
furanocoumarins, have been demonstrated to inhibit enteric
CYP3A4 and P-gp [26–32]. However, most of these con-
clusions were drawn essentially from in vitro studies.
Until recently, a human study has pointed out that lack
of interaction with felodipine when furanocoumarin-free
grapefruit juice was coadministered [33]. As a result, 6 ,7  -
dihydroxybergamottin and bergamottin can be thought
responsible for the inhibition of intestinal CYP3A4 and P-
gp resulting from grapefruit juice consumption. Although
Citrus aurantium belongs to the same genus as grapefruit,
our HPLC analysis showed no obergamottin in both Zhi
Ke and Zhi Shi decoctions. However, detection of 6 ,7  -
dihydroxybergamottin in the decoctions was not attempted
because of the unavailability of authentic standard. The
opposite inﬂuences on tacrolimus blood levels between
grapefruit juice and Zhi Shi decoction might be in part
attributabletothepresenceoffuranocoumarinsingrapefruit
juice but not in Zhi Shi.
The origins of Zhi Ke and Zhi Shi are from the fruits
of the same plant, but harvested at diﬀerent seasons. The
diﬀerentinﬂuencesontacrolimuspharmacokineticsbetween
coadministrations of Zhi Ke and Zhi Shi might be due to
the change of constituents during fruit ripening. ThroughEvidence-Based Complementary and Alternative Medicine 5
comparing the concentrations of naringin and naringenin
in two decoctions, the involvement of these two ﬂavanones
in the interaction can be excluded. On the other hand,
the diﬀerence of parts used between Zhi Ke and Zhi Shi
might be another possible reason to result in diﬀerent eﬀect.
What constituents in Zhi Shi actually resulted in the marked
decrease of blood tacrolimus levels is still on the agenda of
our future research.
Because the elimination half-lives of tacrolimus between
treatments with tacrolimus alone and coadministration with
Zhi Shi were not signiﬁcantly diﬀerent, we thus propose
that the decreased bioavailability of tacrolimus caused by
Zhi Shi should primarily occur at the absorption site. Two
mechanismsaﬀectingthefateoftacrolimusatabsorptionsite
havebeenidentiﬁed:pumpedoutbyP-gpinintestinesurface
at the ﬁrst stage and, subsequently, the residuals metabolized
byCYP3A4inintestineandliver[11–13].Therefore,reduced
oral absorption of tacrolimus may be associated with the
activation of P-gp and/or CYP3A4.
To explore the association of P-gp with the interaction,
transport assay of rhodamine 123 was conducted using LS
180 cells. As shown in Figure 3, contrary to verapamil (a
positive control as P-gp inhibitor), Zhi Shi decreased the
intracellularaccumulationofrhodamine 123, indicating that
the eﬄux function of P-gp was activated. The magnitude
of P-gp activation was found not proportional to the
concentration of Zhi Shi, which might be accounted for by
the complex chemical constituents in Zhi Shi decoction. We
contemplate that it is likely that some constituents inhibiting
P-gp were coexistent in Zhi Shi decoction and counteracted
partial P-gp induction eﬀect at high concentration. Based on
this in vitro result, the increased P-gp activity might in part
explain the decreased blood levels of tacrolimus in rats as
illustrated in Figure 4.
With regard to the eﬀect on CYP3A4, grapefruit juice
has been found to decrease intestinal CYP3A4 protein
expression [34, 35], which may explain the increased blood
levels of tacrolimus [36]. On the contrary, the decreased
blood levels of tacrolimus caused by Zhi Shi might stem
from induction of CYP3A4 activity. However, an in vitro
study has revealed that Zhi Shi exerted weak inhibition on
CYP3A4 activity in testosterone 6-hydroxylation by human
liver microsomes [37], which was apparently not consistent
with our in vivo evidence. This in vitro-in vivo discrepancy
led us to propose that most constituents in herbal decoctions
were hydrophilic and subjected to metabolic transforma-
tions in the gut lumen before entering the enterocytes
and hepatocytes. How CYP3A4 is involved in herb-drug
interaction requires a diﬀerent approach from drug-drug
interaction in western medicines. Therefore, understanding
thepresystemicmetabolismofherbalconstituentsisessential
for the establishment of a rational model more mimicking
the biological system.
In conclusion, Zhi Shi signiﬁcantly decreased the oral
bioavailability of tacrolimus in rats, whereas Zhi Ke exerted
no inﬂuence. We suggest that Zhi Shi be contraindicated for
transplant patients treated with tacrolimus to reduce the risk
of allograft rejection.
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